Rifaximine versus neomycin in the treatment of portosystemic encephalopathy.
In 14 patients with cirrhosis and chronic portosystemic encephalopathy, the effectiveness of treatment with a new non-assorbable antibiotic (rifaximine) was compared to neomycin. The parameters evaluated were: bradylalia, flapping tremor, performance, visual evoked potentials and the trial making test. Both treatments were combined with lactulose. The analysis of results showed a rate of positive results in the patients treated with rifaximine greater than that with neomycin. Differences, however, were not significant.
Di Piazza
S
S
Clinica Medica R Divisione di Medicina, Ospedale V Cervello, Universitì di Palermo, Italy.
Gabriella Filippazzo
M
M
Valenza
L M
LM
Morello
S
S
Pastore
L
L
Conti
A
A
Cottone
S
S
Pagliaro
L
L
D002908:Chronic Disease; D005260:Female; D006501:Hepatic Encephalopathy / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009355:Neomycin / Q000627:therapeutic use*; D012294:Rifamycins / Q000627:therapeutic use*; D000078262:Rifaximin
D012294:Rifamycins; D009355:Neomycin; D000078262:Rifaximin